ArticleCancer diagnosis & prognosis
GRIm Score Predicts Curative Conversion Surgery in Unresectable Gastric Cancer.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Conversion surgery can prolong survival in initially unresectable gastric cancer when curative (R0) resection is achieved; however, pre-treatment predictors of R0 conversion remain limited. We investigated whether the Gustave Roussy Immune (GRIm) score predicts R0 resection and survival in patients considered for conversion surgery. Patients and Methods: We retrospectively analyzed 57 patients with unresectable advanced gastric cancer treated with systemic chemotherapy from January 2019 to July 2025. Patients were classified as achieving conversion (AC; conversion surgery with R0 resection) or non-conversion (NC). The GRIm score (albumin, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio) and clinicopathological variables were evaluated as predictors of R0 resection using univariate and multivariate logistic regression. Overall survival (OS) was assessed using the Kaplan-Meier method. Results: Ten patients (17.5%) achieved R0 resection. The AC group had lower GRIm scores and a more favorable Yoshida classification than the NC group, and intestinal-type histology was more frequent in the AC group. In multivariate analysis, a low GRIm score (0-1) and Yoshida classification C1-2 were independently associated with R0 resection. OS was significantly longer in patients with low GRIm scores than in those with high scores. Conclusion: The GRIm score is an accessible pre-treatment biomarker associated with successful R0 conversion surgery and improved survival in unresectable gastric cancer and may complement the Yoshida classification in candidate selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.